IRCT201106214856N2
Completed
Phase 2
Outcoms of intravitreal injection of bevacizumab in patients with acute Branch retinal Vein Occlusion(BRVO)
Vice chancellor for research, Baqiyatallah University of Medical Science0 sites20 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Branch Retinal Vein occlusion.
- Sponsor
- Vice chancellor for research, Baqiyatallah University of Medical Science
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion: Patients with initial diagnose of branch retinal vein occlusion(BRVO) based on examination with Slit Lamp; Less than one week of symptoms onset.
- •Exclusion: Other pathologies of retinal vessels beside BRVO based on flurcein angiography(FA); Patients that have recevied any medication for BRVO.
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 3
Effect of diclofenac eye drop and Bevacizumab and Triamcinolone in preventing part of the retina edemaDiabetic retinopathy.Diabetic retinopathyIRCT2017050833875N1Vice chancellor For Research Of Ahvaz Jundishapur University of Medical Sciences45
Recruiting
Phase 4
Efficacy of bevacizumab by intravitreal route in choroidal neovascular membrane of eye.CTRI/2016/09/007288Govt medical college and sir takhtsinhji hospital bhavnagr30
Active, not recruiting
Not Applicable
Silmän sisäisten lääkeainepistosten aikaan saama hermoston uudelleen muokaantuvuusEUCTR2012-000765-20-FIKuopion yliopistollinen sairaala/silmätautien poliklinikka
Completed
Not Applicable
Evaluate the effect of intravitreal Bevacizumab injection for ocular proliferative diseaseschoroidal neovascularization,proliferative diabetic retinopathy, central retinal vein occlusion neovascular glaucomaJPRN-UMIN000020467agasaki University Hospital90
Not yet recruiting
Not Applicable
The response of intravitreal bevacizumab in the treatment of intraocular neovascularizatioOcular neovascularizationJPRN-UMIN000009389Osaka University Hospital80